LDS/Medical Tests/Prenatal (Obstetrics) Carrier Screening for Inherited Genetic Conditions (Genesys Carrier Panel, LabCorp Inheritest®, UNITY Fetal Risk screen)

Prenatal (Obstetrics) Carrier Screening for Inherited Genetic Conditions (Genesys Carrier Panel, LabCorp Inheritest®, UNITY Fetal Risk screen)

Genetic carrier screening is essential for identifying inherited pathogenic variants that may predispose offspring to congenital abnormalities and genetic disorders. The Comprehensive Obstetrics Carrier Screening Panel employs advanced genetic technologies, including next-generation sequencing (NGS) and multiple ligation-dependent probe amplification (MLPA), to detect variants in 145 genes associated with hereditary conditions.

This test is designed for women who are pregnant or planning pregnancy to assess their carrier status for multiple autosomal recessive and X-linked conditions. Additionally, it includes an 11-gene high-frequency pan-ethnic panel, capturing prevalent pathogenic variants across diverse ethnic groups. The screening also provides targeted detection for high-priority conditions, such as: Fragile X syndrome (FMR1 gene expansion leading to intellectual disability and primary ovarian insufficiency), Duchenne muscular dystrophy (DMD gene mutations causing progressive muscle weakness), Spinal muscular atrophy (SMN1 gene deletions leading to motor neuron degeneration), Alpha thalassemia (HBA1/HBA2 gene deletions resulting in hemoglobin production defects), Cystic fibrosis (CFTR gene mutations causing chronic lung disease and pancreatic insufficiency) and others.

  • Identification of carrier status for autosomal recessive and X-linked genetic disorders
  • Informed reproductive decision-making for obstetric care planning and neonatal management
  • Early intervention and preparedness for conditions requiring specialized neonatal care

Negative (Normal)

  • No pathogenic variants detected.

Positive (Abnormal)

  • Detection of a pathogenic variant in one or more genes, suggesting potential risk for offspring if the reproductive partner carries the same or a related variant.

Further Evaluation: If positive, genetic counseling is recommended to assess reproductive risks and discuss additional testing options, including partner screening and prenatal diagnostic testing such as chorionic villus sampling (CVS) or amniocentesis.

Negative (No pathogenic variants detected)

Next-generation sequencing (NGS), Multiple ligation-dependent probe amplification (MLPA), Sanger sequencing for confirmation of selected variants.

Whole blood (EDTA), Buccal swab, saliva.

Stability

  • Ambient: 3–5 days
  • Refrigerated: 7–14 days
  • Frozen: Unstable
Individual test to confirm any mutation or variation.
1-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login